Clinical trial
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss…
NCT00088283 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00088283 |
|---|---|
| Title | Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) |
| Official title | A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | pegaptanib sodium |
| Enrollment | 90 |
| Start date | May 1, 2004 |
| First posted | Jul 26, 2004 |
| Last update posted | Jan 19, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: